Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03820947 · ClinicalTrials.gov registry record · NA
VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial
A NA study, sponsored by Medtronic Endovascular.
- Terminated
- Registry status
- NA
- Development phase
- 506
- Enrollment target
NCT03820947: Clinical Trial NA study, sponsored by Medtronic Endovascular.
NCT03820947 is a NA study that was terminated before completion, run by Medtronic Endovascular. The registered enrollment target is 506 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03820947, a NA study, was terminated before completion, sponsored by Medtronic Endovascular.
- TERMINATED
- Registry status
- NA
- Development phase
- 506 participants
- Enrollment target
Study Summary
Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease
Primary Outcome
Measured by a validated, patient-centered venous treatment satisfaction questionnaire - early (VenousTSQe). Total score ranges from 0-36, and a higher score means a higher peri-procedural venous treatment satisfaction.
Interventions
- DEVICE VenaSeal™ System
- DEVICE Endothermal Ablation (ETA)
- PROCEDURE Surgical Stripping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2025-11-10 |
| Phase | NA |
Why NCT03820947 stopped before completion
NCT03820947 is an interventional study that assigns participants to a tested intervention. The registered 506 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 3 interventions - of which VenaSeal™ System is the first listed.
NCT03820947 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03820947 about?
NCT03820947 is a clinical study titled "VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial". Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease
What is the current status of trial NCT03820947?
This trial is currently terminated. It is a NA study. The enrollment target is 506 participants. The study started on 2020-02-05. Estimated completion is 2025-11-10.
What interventions are being tested in trial NCT03820947?
The interventions under investigation include: VenaSeal™ System (DEVICE), Endothermal Ablation (ETA) (DEVICE), Surgical Stripping (PROCEDURE).
Who is sponsoring clinical trial NCT03820947?
This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03820947's enrollment target sits among peer trials
506 193rd of 2000 higher than 1,808 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05069428 · 506 participants · Phase 4
Delirium Reduction With Ramelteon
- NCT05797168 · 506 participants · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI